Europe
The increase reflects the positive financial impact COVID-19 has had on the European diagnostic company’s bottom line.
Novartis plans to make the drugs available to government, non-governmental organizations (NGOs) and other institutional customers in up to 79 countries at no profit.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
AC Immune, based in Lausanne, Switzerland, initiated the second highest dosing group in its Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease. The move is based on encouraging interim data from the initial dosing cohort.
Phase I data from the COVID-19 vaccine under development by AstraZeneca and Oxford University’s Jenner Institute is showing a robust defense against the novel coronavirus that has infected more than 13 million people across the globe.
AstraZeneca released positive data from the Phase III THALES trial of Brilinta (ticagrelor) used twice a day with an aspirin.
Together, the companies will develop Tumor Treating Fields with Merck’s anti-PD-1 therapy, Keytruda for the treatment of non-small cell lung cancer (NSCLC).
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
PRESS RELEASES